RAFAEL HOLDINGS, INC. Shares Issued, Value, Share-based Payment Arrangement, Forfeited
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- RAFAEL HOLDINGS, INC. shares issued, value, share-based payment arrangement, forfeited for the quarter ending 2024-04-30 was $0.00.
- RAFAEL HOLDINGS, INC. shares issued, value, share-based payment arrangement, forfeited for the quarter ending 2024-01-31 was $915.00K.
- RAFAEL HOLDINGS, INC. shares issued, value, share-based payment arrangement, forfeited for the quarter ending 2023-10-31 was $915.00K, a 22.46% decline year-over-year.
- RAFAEL HOLDINGS, INC. shares issued, value, share-based payment arrangement, forfeited for the quarter ending 2023-01-31 was -$265.00K.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, Forfeited 3 month | Shares Issued, Value, Share-based Payment Arrangement, Forfeited 12 month |
|---|---|---|
| 2024-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | |
| 2024-01-31 | $915.00K 10-Q · filed 2024-03-14 | |
| 2023-10-31 | $915.00K 10-Q · filed 2023-12-14 | |
| 2023-07-31 | $915.00K 10-Q · filed 2025-06-11 | |
| 2023-01-31 | -$265.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-06-13 | |
| 2022-10-31 | $1.18M 10-Q · filed 2022-12-13 | |
| 2021-10-31 | $7.85M 10-Q · filed 2022-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |